BIOMERIEUX overview

Global In Vitro Diagnostics Leader bioMérieux Celebrates the Opening of the Molecular and Genomic Innovation Center at the Navy Yard in Philadelphia PR Newswire PHILADELPHIA, Sept. 18, 2024 bioMérieux's Latest 32,000 sq. ft. Global Food Safety and Quality Site is Home to the xPRO ™ Program that Rapidly Innovates Cutting-Edge Molecular Assays in Partnership with Industry Leaders PHILADELPHIA , Sept. 18, 2024 /PRNewswire/ -- bioMérieux, a world leader in in vitro diagnostics, celebrates the...

Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market. This press release features multimedia. View the full release here:...

bioMérieux Introduces GENE-UP® ENVIROPRO™ PR Newswire CHICAGO, Feb. 2, 2023 Only Environmental Swabbing Assay That Simultaneously Detects Both Salmonella and Listeria Through a Single Enriched Sample with PCR Confirmation, On-Site Solution is Now Available for Implementation, Strengthening Company's Overall Food Safety Portfolio CHICAGO , Feb. 2, 2023 /PRNewswire/ -- bioMérieux , a world leader in in vitro diagnostics, announces the availability of GENE-UP ® ENVIROPRO™, the only assay of...

French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance PR Newswire LABÈGE, TOULOUSE, MARCY L'ETOILE and LYON, France, Jan. 6, 2022 · ARPEGE is designed to achieve solutions to antibiotic resistance by combining preventive, diagnostic, therapeutic and economic approaches for the first time. · Led by the French biotech company Antabio, the ARPEGE consortium is acting jointly with bioMérieux, Hospices Civils de Lyon, and...

Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR ™ CCL14 Test. The NEPHROCLEAR ™ CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways. The companies intend to commercially launch the NEPHROCLEAR ™ CCL14 Test in western Europe in 2022. This press...

bioMérieux to Showcase its Full Suite of Nutraceutical Testing Solutions, Including the Recently Released GENE-UP® NUTRAPLEX PRO™ Assay CHICAGO, IL / ACCESSWIRE / October 5, 2021 / bioMérieux , a world leader in the field of in vitro diagnostics, will exhibit at SupplySide West 2021, the leading trade show for health and nutrition industry professionals focused on dietary supplements, beverages, functional foods, personal care, and sports nutrition innovation. SupplySide West 2021 will take...

Regulatory News: An Ordinary and Extraordinary Shareholders’ Meeting of bioMérieux (Paris:BIM) is called at 2:00 p.m. on May 20, 2021 at 376 Chemin de l'Orme, Marcy l'Étoile (69280), France. The practical information about voting, the agenda and proposed resolutions are outlined in the preliminary notice published in the French Bulletin of Compulsory Legal Announcements ( Bulletin des Annonces Légales Obligatoires ) on April 9th, 2021 (number 43), and on Company’s website at...